The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies.As ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across eight U.S. sites.

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

In this study, researchers aimed to determine whether BCMA-directed CAR T-cell therapy is a feasible first-line option for newly diagnosed multiple myeloma patients who are ineligible for ASCT.

Researchers designed CAR T cells that locally release VEGF-blocking molecules, weakening tumor defenses and boosting immune attack. The therapy slowed tumor growth and improved survival in cancer ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.